Antipsychotics, also known as neuroleptics, are a specialized class of psychotropic medications primarily used to manage psychosis—including delusions, hallucinations, paranoia, or disordered thought. In the 2026 pharmaceutical landscape, these drugs have evolved beyond simple sedation toward precision modulation of neurotransmitters to restore cognitive and emotional balance.
1. Major Classifications of Antipsychotics
The industry categorizes these agents based on their chronological development and their specific pharmacological profiles:
| Category | Primary Mechanism | Common Examples |
| First-Generation (Typical) | Strong D2 (Dopamine) receptor antagonism. Effective for “positive” symptoms but carries higher motor side-effect risks. | Haloperidol, Chlorpromazine, Fluphenazine. |
| Second-Generation (Atypical) | Combined D2 and 5-HT2A (Serotonin) antagonism. Lower risk of motor issues but requires monitoring for metabolic effects. | Quetiapine, Olanzapine, Risperidone, Clozapine. |
| Third-Generation (Partial Agonists) | Acts as a “dimmer switch” for dopamine; stabilizes activity rather than purely blocking it. | Aripiprazole, Brexpiprazole, Cariprazine. |
2. 2026 Industry Shift: Long-Acting Injectables (LAIs)
One of the most significant trends in 2026 is the rapid transition from daily oral pills to Long-Acting Injectables (LAIs).
Adherence Breakthrough: Clinical data in 2026 shows that LAIs reduce 30-day hospital readmission rates by up to 77% compared to oral therapy by eliminating the “forgotten dose” factor.
Extended Windows: New formulations approved in 2025-2026, such as once-bimonthly or even quarterly injections, provide consistent drug plasma levels, significantly reducing the “peaks and valleys” associated with daily metabolism.
Subcutaneous Innovation: The market is seeing a surge in Subcutaneous (SC) Atypical Injections, which are less invasive than traditional intramuscular shots and can sometimes be administered in outpatient settings with higher patient comfort.
3. Significance of Antipsychotic Manufacturing in India (2026)
As of 2026, India serves as a critical global hub for mental health pharmacotherapy, projected to grow at a 30.3% CAGR in the Asia-Pacific region.
Complex Generic Leadership: Indian CDMOs are at the forefront of developing bioequivalent versions of high-value atypical antipsychotics, ensuring that global healthcare systems can manage the rising prevalence of schizophrenia and bipolar disorder affordably.
Specialized Neuro-Blocks: Leading manufacturing units in India now feature dedicated, AI-monitored Psychotropic Blocks to ensure 100% containment and prevent cross-contamination of these highly potent molecules.
Digital-Therapeutic Integration: A 2026 trend among Indian exporters is the “Medication + App” model, where antipsychotic packaging includes QR codes for Companion Apps that help patients track symptoms and adherence in real-time.
Pediatric and Geriatric Customization: India leads in producing specialized formats like Orally Disintegrating Tablets (ODT) and taste-masked liquids for patients who have difficulty swallowing traditional pills.
4. Why Healthy Inc. is Your Strategic Sourcing Partner
Sourcing psychiatric medications requires a partner who understands the sensitivity of CNS (Central Nervous System) integrity. Healthy Inc. acts as your technical bridge:
Strategic Sourcing Hub: We are associated with multiple state-of-the-art manufacturing units specializing in advanced neuro-therapies. Whether you need Aripiprazole LAIs, Quetiapine ER tablets, or the latest Third-Generation agents, we match you with the right facility.
Pharmacist-Led Technical Vetting: We provide “straight answers” on Bioequivalence and Metabolic Profiles. Our team vets every batch to ensure precise dissolution rates, which is vital for maintaining the narrow therapeutic window required for psychiatric stability.
Regulatory & Dossier Mastery: We simplify international registration by providing full CTD/ACTD dossiers, stability data for all climate zones, and bioequivalence reports required for global tenders.
2026 Pipeline Access: Through our network, we provide access to the latest innovations, including Muscarinic-receptor agonists and mGlu2/3 modulators, giving your brand a competitive edge in the evolving mental health market.
Showing all 15 results
Amitriptyline & Chlordiazepoxide Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended, Film-Coated Tablet, packed in high-barrier Alu-Alu blister strips to ensure the stability of the benzodiazepine component.
Active Ingredient Strength Primary Clinical Function Amitriptyline (as HCl) USP/BP 12.5 mg / 25 mg The Antidepressant Anchor: Elevates mood and energy levels by modulating neurotransmitter reuptake. Chlordiazepoxide USP/BP 5 mg / 10 mg The Anxiolytic Shield: Provides rapid relief from nervousness, agitation, and muscle tension. Excipients Proprietary Matrix Bio-Synchronized System: Engineered to ensure the rapid onset of the anxiolytic effect while the antidepressant effect builds over time. Amitriptyline Tablet
FreeProduct Composition & Strength
We supply this product as Film Coated Tablets (often Blue, Yellow, or Orange depending on strength) to mask the intensely bitter taste of the API.
Active Ingredient Strength (Standard) Primary Role Amitriptyline HCl IP/BP/USP 10 mg Neuropathic Pain / Migraine / Sleep Amitriptyline HCl IP/BP/USP 25 mg Pain / Depression Initiation Amitriptyline HCl IP/BP/USP 50 mg Major Depression (Maintenance) Amitriptyline HCl IP/BP/USP 75 mg High Potency / Severe Depression Amoxapine Tablets
FreeProduct Composition & Strength
We supply this product in a full range of strengths to allow for precise clinical titration, packed in high-barrier Alu-Alu blister strips.
Active Ingredient Strength Primary Clinical Function Amoxapine USP/BP 25 mg / 50 mg The Titration Unit: Used for gradual dose escalation to minimize initial sedative effects. Amoxapine USP/BP 100 mg The Standard Anchor: The primary maintenance dose for outpatients with moderate depression. Amoxapine USP/BP 150 mg The High-Potency Payload: For hospitalized patients with severe psychotic or endogenous depression. Chlorpromazine Tablets
FreeProduct Composition & Available Strengths
We provide this therapeutic in a versatile range of strengths to allow for the precise dose titration required in specialized psychiatric medicine.
Active Ingredient Standard Strengths Primary Clinical Target Chlorpromazine HCl IP/BP/USP 25 mg Low-Dose Titration: For anxiety, pediatric hiccups, or elderly care. Chlorpromazine HCl IP/BP/USP 50 mg Maintenance Therapy: For stable outpatient management of schizophrenia. Chlorpromazine HCl IP/BP/USP 100 mg Acute Crisis Control: High-potency dosing for acute manic or psychotic states. Clozapine Tablets
FreeProduct Composition & Available Titration Strengths
Because Clozapine demands highly delicate, low-dose initial titration to protect the patient’s cardiovascular profile, we manufacture the full compendial strength spectrum.
Active Ingredient Monograph Available Strengths Formulation Matrix Delivery System Primary Clinical Application Clozapine USP / BP / IP 25 mg Oral Solid Uncoated Micro-Tablet Introductory Safety Titration: Mandatory low-dose baseline format utilized exclusively for the initial day 1 and day 2 dose-escalation phase to prevent orthostatic shock. Clozapine USP / BP / IP 50 mg Oral Solid Uncoated Micro-Tablet Intermediate Dose Step-Up: Mid-tier titration strength engineered to scale up systemic tolerance during weeks 1 and 2. Clozapine USP / BP / IP 100 mg Oral Solid Compressed Tablet The Core Commercial Volume: First-line international standard target maintenance strength for adult refractory schizophrenia management. Fluoxetine Capsules
FreeFluoxetine capsules, commonly known by the brand name Prozac (accessdata.fda.gov), contain the active antidepressant fluoxetine hydrochloride along with several inactive ingredients that vary by manufacturer and dosage strength.
Fluphenazine Injection
FreeProduct Composition & Strength
We supply this product as a Sterile Oily Solution in Amber Glass Ampoules or Vials.
Active Ingredient Strength Type Fluphenazine Decanoate USP/BP 25 mg 1 ml Ampoule / Vial Fluphenazine Decanoate USP/BP 12.5 mg 0.5 ml Ampoule (Starter Dose) Vehicle Sesame Oil Depot Base Preservative Benzyl Alcohol 1.5% v/v (In Vials) *Pack Sizes: Tray of 5 Ampoules, 10 Ampoules, or 10 ml Multi-Dose Vial.
Haloperidol Tablets
FreeProduct Composition & Strength
We supply this product as Uncoated Tablets (often small, white or yellow). We offer a wide range of strengths for precise titration.
Active Ingredient Strength (Standard) Primary Role Haloperidol USP/BP 1.5 mg Geriatric / Maintenance Haloperidol USP/BP 5 mg Standard Acute Dose Haloperidol USP/BP 10 mg Severe Psychosis / Mania Haloperidol USP/BP 20 mg Treatment Resistant Cases Naloxone Injection
FreeProduct Composition & Strength
We supply this product as a Sterile Solution in Glass Ampoules or Pre-filled Syringes.
Active Ingredient Strength Format Naloxone Hydrochloride USP/BP 400 mcg (0.4 mg) 1 ml Ampoule (Standard Adult) Naloxone Hydrochloride USP/BP 20 mcg (0.02 mg) 1 ml Ampoule (Neonatal/Pediatric) Excipients Methylparaben / Propylparaben Preservative (in Multi-dose Vials) *Pack Sizes: Tray of 10 Ampoules or Box of 10 Vials.
Olanzapine Injection
FreeProduct Composition & Strength
We supply this product as a Sterile Lyophilized Powder (Yellow Cake) in glass vials.
Active Ingredient Strength Reconstitution Requirement Olanzapine BP/USP 10 mg Requires 2.1 ml of Sterile Water for Injection Excipients Lactose Monohydrate / Tartaric Acid Bulking Agent / Solubilizer *Pack Sizes: Single Vial. (Produces a clear, yellow solution upon reconstitution).
Olanzepine Tablet
FreeProduct Composition & Available Strengths
We supply Olanzapine in standard, exact strengths to facilitate initial titration phases and safe daily maintenance therapy.
Active Ingredient Available Strengths Primary Clinical Target Olanzapine IP / BP / USP 2.5 mg Introductory Titration: For low-dose introductory cycles, elderly adjustment, or sensitive patient profiles. Olanzapine IP / BP / USP 5 mg Standard Maintenance: The baseline daily dosage for long-term schizophrenic and bipolar maintenance. Olanzapine IP / BP / USP 10 mg Acute Crisis Control: High-potency therapeutic dosing to stabilize acute manic or severe psychotic episodes. Prochlorperazine Tablets
FreeProchlorperazine Maleate Tablets IP 5 mg
Each Uncoated Tablet contains :
Prochlorperazine Maleate IP 5 mgUsage: – control severe nausea and vomiting
Category: – Antipsychotic / CNS Drugs
Therapeutic category: – Antipsychotic
Risperidone Tablets
FreeRisperidone Tablets 1 mg
Each film coated tablet contains:
Risperidone IP 1 mgRisperidone Tablets 2 mg
Each film coated tablet contains:
Risperidone IP 2 mgRisperidone Tablets 3 mg
Each film coated tablet contains:
Risperidone IP 3 mgRisperidone Tablets 4 mg
Each film coated tablet contains:
Risperidone IP 4 mgRisperidone Tablets 1 mg
Each film coated tablet contains:
Risperidone BP 1 mgRisperidone Tablets 2 mg
Each film coated tablet contains:
Risperidone BP 2 mgRisperidone Tablets 3 mg
Each film coated tablet contains:
Risperidone BP 3 mgRisperidone Tablets 4 mg
Each film coated tablet contains:
Risperidone BP 4 mgUsage: – treat certain mental/mood disorders
Category: – Anti Anxiety drugs
Therapeutic category: – Antipsychotic, Antidepressant, CNS Drugs, Anti Anxiety
Zaleplon Capsules
FreeZaleplon capsules (commonly known by the brand name Sonata) are nonbenzodiazepine hypnotics used for the short-term treatment of insomnia. They are formulated to help patients fall asleep quickly.
Ziprasidone Capsules
FreeZiprasidone capsules (widely known by the brand name Geodon) are atypical antipsychotic medications used to treat schizophrenia and bipolar disorder.
